BIOMAT Database Logo BIOMAT Database Logo

Discovery of a Potent and Selective Degrader for USP7. 2022

Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China.

The tumor suppressor p53 is the most frequently mutated gene in human cancer and more than half of cancers contain p53 mutations. The development of novel and effective therapeutic strategies for p53 mutant cancer therapy is a big challenge and highly desirable. Ubiquitin-specific protease 7 (USP7), also known as HAUSP, is a deubiquitinating enzyme and proposed to stabilize the oncogenic E3 ubiquitin ligase MDM2 that promotes the proteosomal degradation of p53. Herein, we report the design and characterization of U7D-1 as the first selective USP7-degrading Proteolysis Targeting Chimera (PROTAC). U7D-1 showed selective and effective USP7 degradation, and maintained potent cell growth inhibition in p53 mutant cancer cells, with USP7 inhibitor showing no activity. These data clearly demonstrated the practicality and importance of PROTAC as a preliminary chemical tool for investigating USP7 protein functions and a promising method for potential p53 mutant cancer therapy.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000076084 Ubiquitin-Specific Peptidase 7 A ubiquitinyl hydrolase that deubiquitinates several proteins with critical roles in DNA REPAIR, cell growth, and survival, including TUMOR SUPPRESSOR PROTEIN P53; MDM-2 PROTEIN; and PTEN PHOSPHOHYDROLASE. It also stabilizes herpesvirus 1 trans-acting transcriptional protein VMW110 during HSV-1 infection, contributing to its function as a TRANS-ACTIVATOR. HAUSP Protein,Herpesvirus-Associated Ubiquitin-Specific Peptidase,USP7 Protein,Herpesvirus Associated Ubiquitin Specific Peptidase,Peptidase 7, Ubiquitin-Specific,Peptidase, Herpesvirus-Associated Ubiquitin-Specific,Ubiquitin Specific Peptidase 7,Ubiquitin-Specific Peptidase, Herpesvirus-Associated
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D043222 Ubiquitin Thiolesterase A thioester hydrolase which acts on esters formed between thiols such as DITHIOTHREITOL or GLUTATHIONE and the C-terminal glycine residue of UBIQUITIN. Neuron Cytoplasmic Protein 9.5,PARK5 Protein,Parkinson Disease 5 Protein,UCHL1 Protein,Ubiquitin C-Terminal Esterase,Ubiquitin C-Terminal Hydrolase,Ubiquitin Carboxy-Terminal Esterase,Ubiquitin Carboxy-Terminal Hydrolase,Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1,Uch-L1 Protein,C-Terminal Esterase, Ubiquitin,C-Terminal Hydrolase, Ubiquitin,Carboxy-Terminal Esterase, Ubiquitin,Carboxy-Terminal Hydrolase, Ubiquitin,Esterase, Ubiquitin C-Terminal,Esterase, Ubiquitin Carboxy-Terminal,Hydrolase, Ubiquitin C-Terminal,Hydrolase, Ubiquitin Carboxy-Terminal,Thiolesterase, Ubiquitin,Ubiquitin C Terminal Esterase,Ubiquitin C Terminal Hydrolase,Ubiquitin Carboxy Terminal Esterase,Ubiquitin Carboxy Terminal Hydrolase,Ubiquitin Carboxyl Terminal Hydrolase Isozyme L1,Uch L1 Protein
D044767 Ubiquitin-Protein Ligases A diverse class of enzymes that interact with UBIQUITIN-CONJUGATING ENZYMES and ubiquitination-specific protein substrates. Each member of this enzyme group has its own distinct specificity for a substrate and ubiquitin-conjugating enzyme. Ubiquitin-protein ligases exist as both monomeric proteins multiprotein complexes. Ubiquitin-Protein Ligase,E3 Ligase,E3 Ubiquitin Ligase,Ubiquitin Ligase E3,Ubiquitin-Protein Ligase E3,Ligase E3, Ubiquitin,Ligase E3, Ubiquitin-Protein,Ligase, E3,Ligase, E3 Ubiquitin,Ligase, Ubiquitin-Protein,Ligases, Ubiquitin-Protein,Ubiquitin Ligase, E3,Ubiquitin Protein Ligase,Ubiquitin Protein Ligase E3,Ubiquitin Protein Ligases
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D059748 Proteolysis Cleavage of proteins into smaller peptides or amino acids either by PROTEASES or non-enzymatically (e.g., Hydrolysis). It does not include Protein Processing, Post-Translational. Protein Degradation,Protein Digestion,Degradation, Protein,Degradations, Protein,Digestion, Protein,Digestions, Protein,Protein Degradations,Protein Digestions,Proteolyses

Related Publications

Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery and characterization of highly potent and selective allosteric USP7 inhibitors.
February 2018, Nature chemical biology,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
April 2023, Journal of the American Chemical Society,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader.
April 2024, Journal of medicinal chemistry,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
August 2022, Journal of medicinal chemistry,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
December 2020, Journal of medicinal chemistry,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities.
June 2024, Bioorganic & medicinal chemistry letters,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
February 2023, Journal of medicinal chemistry,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
September 2022, European journal of medicinal chemistry,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
January 2023, Bioorganic & medicinal chemistry letters,
Yuan Pei, and Jingfeng Fu, and Yunkai Shi, and Mengmeng Zhang, and Guanghao Luo, and Xiaomin Luo, and Ning Song, and Tian Mi, and Yaxi Yang, and Jia Li, and Yubo Zhou, and Bing Zhou
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity.
May 2020, Journal of medicinal chemistry,
Copied contents to your clipboard!